Marksans Pharma shares in focus after block deals worth ₹257 crore

As of the March-end quarter, OrbiMed Asia IV Mauritius FVCI Ltd had a 10.88% stake in Marksans Pharma.

Leave a Reply

Your email address will not be published. Required fields are marked *